Lupin receives USFDA approval for Potassium Chloride for Oral Solution

26 Nov 2018 Evaluate

Lupin has received approval for its Potassium Chloride for Oral Solution USP, 20 mEq from the United States Food and Drug Administration (USFDA) to market a generic version of Pharma Research Software Solution LLC’s Potassium Chloride for Oral Solution, 20 mEq.

Lupin’s Potassium Chloride for Oral Solution USP, 20 mEq is the generic version of Pharma Research Software Solution, LLC’s Potassium Chloride for Oral Solution, 20 mEq. It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.

Potassium Chloride for Oral Solution USP, 20 mEq had annual sales of approximately $105 million in the US (IQVIA MAT September 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2071.35 -26.30 (-1.25%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×